Scribe Raises $129 Million in Rare Gene Editing IPO

Scribe has raised $129 million in an initial public offering, a rare gene editing IPO in a biotech market that has seen few new listings.

BioPharma Dive reported the deal, noting its scarcity value: gene editing companies have largely stayed away from the public markets amid a prolonged slowdown in biotech financings.

The $129 million raise marks Scribe as one of the few gene editing developers to test public-market appetite in the current environment. Most peers in the field have turned to private funding rounds, partnerships, or licensing deals rather than pursuing listings.

The IPO stands out against the broader backdrop. Biotech initial public offerings have become infrequent since the sector's funding boom ended, and gene editing specifically has produced even fewer market debuts. A completed listing of this size signals that selective investors remain willing to back gene editing platforms when the technology and data justify it.

For Scribe, the $129 million provides fresh capital to advance its gene editing programs. For the sector, the offering offers a data point that the IPO window, while narrow, has not closed entirely for gene editing companies with credible science.

Whether Scribe's debut encourages other gene editing developers to follow suit will depend heavily on how the stock trades in its early weeks on the public markets.